Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H48O6.5H2O |
| Molecular Weight | 606.7856 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O
InChI
InChIKey=ILJWZIXNGJYXOL-KFEPNFQESA-N
InChI=1S/C31H48O6.5H2O/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32;;;;;/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36);5*1H2/b26-20-;;;;;/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-;;;;;/m0...../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C31H48O6 |
| Molecular Weight | 516.7092 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Fusidic acid is a anti-bacterial agent, initially isolated from Fusidium coccineum by Godtfredsen et al (Leo Pharma) in 1960. It is discussed that fusidic acid exerts its anti-microbial effect by inhibiting bacterial elongation factor G, thus suppressing the protein synthesis. Fusidic acid is widely used in Europe under the names Fucidin H(fusidic acid / hydrocortisone acetate), Fucidin (fusidic acid / sodium fusidate) and Fucicort (fusidic acid / betamethasone valerate) for the treatment of primary/secondary skin infections and inflammatory dermatoses.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Bacterial elongation factor G |
1.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | FUCIDIN Approved UseFor use in the treatment of primary and secondary skin infections caused by sensitive strains of Staphylococcus aureus, Streptococcusspp and Corynebacterium minutissimum. Primary skin infections that may be expected to respond to treatment with FUCIDIN OINTMENT (sodium fusidate) and CREAM (fusidic acid) include: impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds and infected burns. |
|||
| Curative | FUCICORT Approved UseFUCICORT is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, seborrheic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Fusidic acid: a new antibiotic. | 1962 Mar 10 |
|
| Adverse reactions to intravenous administration of fusidic acid. | 1981 |
|
| Screening for new compounds with antiherpes activity. | 1984 Oct |
|
| Acute renal failure following intravenous fusidic acid. | 1993 |
|
| Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages. | 1994 May-Jun |
|
| Acute renal failure in association with fusidic acid. | 1997 Jun |
|
| Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. | 1997 May |
|
| Antimycobacterial plant terpenoids. | 2001 Nov |
|
| Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. | 2002 Jul 1 |
|
| [Cholestatic icterus induced by the administration of fusidic acid in a cirrhotic patient]. | 2002 Jun 29 |
|
| Sideroblastic anaemia and fusidic acid. | 2003 Feb |
|
| Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. | 2006 Aug |
|
| Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. | 2008 Mar |
|
| Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. | 2009 Apr |
|
| Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | 2010 Dec |
|
| Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid. | 2010 Jun |
|
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | 2013 Dec |
|
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013 Nov |
|
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
A small amount of fucidin ointment(sodium fusidate) or cream (fusidic acid) should be
applied to the lesion 3 or 4 times daily until favourable results are achieved. Futicort cream (fusidic acid / betamethasone valerate) is applied 2 times daily.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:17:47 GMT 2023
by
admin
on
Fri Dec 15 19:17:47 GMT 2023
|
| Record UNII |
7EB01222KN
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000087312
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
SUB20997
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
7EB01222KN
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY | |||
|
76957416
Created by
admin on Fri Dec 15 19:17:48 GMT 2023 , Edited by admin on Fri Dec 15 19:17:48 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |